GRTX · As filed with the SEC
Galera Therapeutics income statement, by fiscal year
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Acquired in-process research and development | 0 | 3,843,000 | — | — |
| Research and development | 349,000 | 3,151,000 | 24,115,000 | 31,012,000 |
| General and administrative | 5,693,000 | 11,002,000 | 22,836,000 | 20,214,000 |
| Restructuring costs | — | — | 2,309,000 | — |
| Write-off of acquired intangible asset | 0 | 2,258,000 | — | — |
| Write-off of goodwill | 0 | 881,000 | — | — |
| Gain on litigation settlement | 0 | (975,000) | — | — |
| Restructuring costs | — | 0 | — | — |
| Loss from operations | (2,542,000) | (20,160,000) | (49,260,000) | (51,226,000) |
| Other income (expenses): | ||||
| Interest income | 248,000 | 554,000 | 1,595,000 | 506,000 |
| Interest expense | — | 0 | (11,414,000) | (11,571,000) |
| Gain on extinguishment of debt | 151,049,000 | — | — | — |
| Gain on sale of dismutase mimetics assets | (3,500,000) | — | — | — |
| Change in fair value of warrant liability | 294,000 | 452,000 | — | — |
| Foreign currency loss | 0 | (6,000) | (3,000) | (1,000) |
| Income (loss) before income tax benefit | 149,049,000 | (19,160,000) | (59,082,000) | (62,292,000) |
| Income tax benefit | 0 | 203,000 | 0 | 70,000 |
| Net income (loss) | 149,049,000 | (18,957,000) | (59,082,000) | (62,222,000) |
| Net loss per share of common stock, basic | — | — | (1.33) | (2.3) |
| Net loss per share of common stock, diluted | — | — | (1.33) | (2.3) |
| Weighted-average shares of common stock outstanding, basic | — | — | 44,549,285 | 27,086,664 |
| Weighted-average shares of common stock outstanding, diluted | — | — | 44,549,285 | 27,086,664 |
| Net income (loss) attributable to common stockholders, basic | 63,524,000 | (18,733,000) | — | — |
| Series B Redeemable Convertible Preferred Stockholders | 76,948,000 | (224,000) | — | — |
| Net income (loss) attributable to common stockholders, diluted | 63,524,000 | (18,733,000) | — | — |
| Series B Redeemable Convertible Preferred Stockholders | 76,948,000 | (224,000) | — | — |
| Net income (loss) per share of common stock, basic | 0.64 | (0.34) | — | — |
| Series B Redeemable Convertible Preferred Stock | 644.89 | (342.89) | — | — |
| Net income (loss) per share of common stock, diluted | 0.64 | (0.34) | — | — |
| Series B Redeemable Convertible Preferred Stock | 644.89 | (342.89) | — | — |
| Weighted-average shares of common stock outstanding, basic | 98,503,430 | 54,633,215 | — | — |
| Series B Redeemable Convertible Preferred Stock | 119,318 | 652 | — | — |
| Weighted-average shares of common stock outstanding, diluted | 98,503,430 | 54,633,215 | — | — |
| Series B Redeemable Convertible Preferred Stock | 119,318 | 652 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.